Teduglutide

A GLP-2 analog approved for short bowel syndrome in patients dependent on parenteral support. GLP-2 acts on the intestinal mucosa, a different receptor from the GLP-1 agonists used for metabolic indications. It is also referred to as Gattex, Revestive, ALX-0600. It is listed here under Healing / Recovery as educational reference, which is not a recommendation to use it.

FDA approved. The FDA has approved at least one product containing this substance for a specific medical use, which means it has been through the agency review process and carries an approved label. Approval is always for named indications in named populations, so it is not a statement that any other use has been evaluated.

~2 h in healthy subjects, ~1.3 h in short bowel syndrome, subcutaneous. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.

Supplied as a lyophilized powder in a single-dose vial, reconstituted with the supplied diluent before use. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.

Commonly listed vial strengths are 5 mg. A vial strength is a market fact about how a product is packaged. It is not a dose, and it says nothing about how much of anything belongs in any person.